Teleflex Incorporated (NYSE:TFX) – Analysts at Leerink Swann raised their Q3 2017 earnings estimates for Teleflex in a note issued to investors on Thursday. Leerink Swann analyst R. Newitter now expects that the medical technology company will post earnings of $2.01 per share for the quarter, up from their previous forecast of $1.99. Leerink Swann currently has a “Market Perform” rating and a $220.00 price objective on the stock. Leerink Swann also issued estimates for Teleflex’s Q4 2017 earnings at $2.46 EPS, FY2017 earnings at $8.32 EPS and FY2018 earnings at $9.45 EPS.

TFX has been the topic of several other reports. Barclays PLC reiterated a “buy” rating on shares of Teleflex in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of Teleflex from a “hold” rating to a “buy” rating and set a $228.00 price target on the stock in a research report on Friday, June 23rd. Deutsche Bank AG increased their price target on shares of Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a research report on Monday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $224.00 price target on shares of Teleflex in a research report on Friday, May 5th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $230.00 price target on shares of Teleflex in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $221.17.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/teleflex-incorporated-nysetfx-expected-to-earn-q3-2017-earnings-of-2-01-per-share.html.

Teleflex (TFX) opened at 214.26 on Monday. The firm has a market capitalization of $9.64 billion, a PE ratio of 44.47 and a beta of 1.05. Teleflex has a one year low of $136.53 and a one year high of $217.97. The stock’s 50 day moving average price is $207.61 and its 200 day moving average price is $195.00.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.89 EPS.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be given a $0.34 dividend. The ex-dividend date is Friday, August 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.63%. Teleflex’s dividend payout ratio is presently 26.00%.

In other news, Director Stuart A. Randle sold 2,500 shares of the stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $205.67, for a total value of $514,175.00. Following the sale, the director now directly owns 7,532 shares in the company, valued at $1,549,106.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John Deren sold 2,246 shares of the stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $194.07, for a total transaction of $435,881.22. Following the completion of the sale, the vice president now owns 3,989 shares in the company, valued at $774,145.23. The disclosure for this sale can be found here. Insiders sold 10,546 shares of company stock worth $2,079,856 over the last quarter. Company insiders own 2.39% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Rafferty Asset Management LLC purchased a new stake in shares of Teleflex during the first quarter worth about $877,000. Creative Planning raised its stake in shares of Teleflex by 69.5% in the second quarter. Creative Planning now owns 3,828 shares of the medical technology company’s stock worth $795,000 after buying an additional 1,569 shares during the period. UBS Asset Management Americas Inc. raised its stake in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock worth $11,692,000 after buying an additional 39,419 shares during the period. Sit Investment Associates Inc. raised its stake in shares of Teleflex by 180.0% in the first quarter. Sit Investment Associates Inc. now owns 2,800 shares of the medical technology company’s stock worth $542,000 after buying an additional 1,800 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Teleflex during the first quarter worth about $2,619,000. Institutional investors and hedge funds own 92.95% of the company’s stock.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.